Using a combination of genetic and pharmacological approaches, we aim to elucidate the underlying mechanisms by which Htr2b inhibition modulates skeletal muscle metabolism and to explore its potential as a therapeutic target for alleviating metabolic diseases associated with obesity. This evidence concerns the gene HTR2B and obesity due to melanocortin 4 receptor deficiency.